ArticleBMC microbiology2016
Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs.
Article in BMC microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Trends and advances inFrontiers in microbiology · 2024Pooled it
- A multi-epitope approach for development of a universal vaccine against leptospirosis.Frontiers in immunology · 2026Article
- Advances in the development of a vaccine for the prevention of human leptospirosis: a review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Review
- Oral Immunization with Yeast-Surface Display of SARS-CoV-2 Antigens inInfectious disease reports · 2025Article
- Expression and Immunogenicity Analysis of Recombinant Leptospira Interrogans Surface Protein LigA in Mouse Model.Veterinary medicine and science · 2025Article
- Enhancement of clinical signs in C3H/HeJ mice vaccinated with a highly immunogenic Leptospira methyl-accepting chemotaxis protein following challenge.PLoS neglected tropical diseases · 2024Article
- Chimeric lipoproteins for leptospirosis vaccine: immunogenicity and protective potential.Applied microbiology and biotechnology · 2024Article
- Designing a broad-spectrum multi-epitope subunit vaccine against leptospirosis using immunoinformatics and structural approaches.Frontiers in immunology · 2024Article
- Immunological characterization of recombinant outer membrane Loa22 protein of local pathogenicVeterinary research forum : an international quarterly journal · 2024Article
- Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.Pathogens (Basel, Switzerland) · 2023Review
- Sph2Vaccines · 2023Article
- Analysis of LruC lipoprotein and identification of peptides candidates for vaccine development and diagnosis of leptospirosis.PloS one · 2023Article
- Going Micro in Leptospirosis Kidney Disease.Cells · 2022Review
- Identification of Leptospiral Protein Antigens Recognized by WC1Infection and immunity · 2022Article
- Challenges for the development of a universal vaccine against leptospirosis revealed by the evaluation of 22 vaccine candidates.Frontiers in cellular and infection microbiology · 2022Article
- Screening of Surface-Exposed Lipoproteins ofFrontiers in microbiology · 2022Article
- The leptospiral LipL21 and LipL41 proteins exhibit a broad spectrum of interactions with host cell components.Virulence · 2021Article
- Article
- Revisiting the Development of Vaccines Against PathogenicFrontiers in immunology · 2021Review
- Vaccine potential of LenA and LcpA proteins ofIranian journal of microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptospirosis is an important reemerging zoonosis, with more than half a million cases reported annually, and is caused by pathogenic Leptospira species. Development of a universal vaccine is one of the major strategic goals to overcome the disease burden of leptospirosis. In this study, a chimeric multi-epitope protein-based vaccine was designed and tested for its potency to induce a specific immune response and provide protection against L. interrogans infection.
resultsThe protein, containing four repeats of six T- and B-cell combined epitopes from the leptospiral outer membrane proteins, OmpL1, LipL32 and LipL21, was expressed and purified. Western blot analysis showed that the recombinant protein (named r4R) mainly expressed in a soluble pattern, and reacted with antibodies raised in rabbit against heat-killed Leptospira and in guinea pigs against the r4R vaccine. Microscopic agglutination tests showed that r4R antisera was immunological cross-reactive with a range of Chinese standard reference strains of Leptospira belonging to different serogroups. In guinea pigs, the r4R vaccine induced a Th1-biased immune response, as reflected by the IgG2a/IgG1 ratio and cytokine production of stimulated splenocytes derived from immunized animals. Finally, r4R-immunized guinea pigs showed increased survival of lethal Leptospira challenges compared with PBS-immunized animals and tissue damage and leptospiral colonization of the kidney were reduced.
conclusionsThe multi-epitope chimeric r4R protein is a promising antigen for the development of a universal cross-reactive vaccine against leptospirosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.